Skip to Content

Promising Efficacy of Zanubrutinib + Venetoclax Treatment in Patients with High-Risk Treatment-Naïve CLL/SLL with Del 17p and/or TP53 Mutation

Zanubrutinib is a next-generation, selective BTK inhibitor designed to have high BTK specificity and minimize off-target effects. In this MEDtalk, Paolo Ghia, Professor, Università Vita-Salute San Raffaele di Milano, presents the preliminary results in patients with del 17p and/or TP53 mutation who received zanubrutinib + venetoclax combination treatment in the SEQUOIA trial.

Paolo Ghia

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top